Analysts expect ConforMIS Inc (NASDAQ:CFMS) to post $18.4 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for ConforMIS’s earnings, with estimates ranging from $17.63 million to $19.55 million. ConforMIS reported sales of $20.25 million in the same quarter last year, which would suggest a negative year over year growth rate of 9.1%. The business is scheduled to report its next earnings results on Thursday, May 11th.
On average, analysts expect that ConforMIS will report full year sales of $18.4 million for the current financial year, with estimates ranging from $80.28 million to $86.05 million. For the next financial year, analysts expect that the firm will report sales of $95.48 million per share, with estimates ranging from $90.29 million to $101.35 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover ConforMIS.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings data on Wednesday, February 15th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.07. The firm earned $21.70 million during the quarter, compared to the consensus estimate of $21.37 million. ConforMIS had a negative net margin of 73.53% and a negative return on equity of 46.41%.
Several brokerages have issued reports on CFMS. Zacks Investment Research upgraded ConforMIS from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Thursday, February 16th. B. Riley reiterated a “buy” rating and set a $7.50 price target on shares of ConforMIS in a report on Thursday, February 16th. Finally, Canaccord Genuity cut ConforMIS from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $7.00 in a report on Thursday, February 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.61.
In related news, Director Philipp Lang sold 9,681 shares of the stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $8.60, for a total transaction of $83,256.60. Following the transaction, the director now owns 519,784 shares of the company’s stock, valued at approximately $4,470,142.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Cerveny sold 3,569 shares of the stock in a transaction dated Friday, February 3rd. The stock was sold at an average price of $8.59, for a total value of $30,657.71. Following the transaction, the insider now directly owns 87,501 shares in the company, valued at approximately $751,633.59. The disclosure for this sale can be found here. In the last three months, insiders have sold 413,859 shares of company stock worth $3,540,670. 9.20% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the company. Papp L Roy & Associates purchased a new position in ConforMIS during the third quarter valued at about $106,000. Numeric Investors LLC bought a new stake in ConforMIS during the fourth quarter worth about $159,000. Trent Capital Management Inc. NC bought a new stake in ConforMIS during the fourth quarter worth about $177,000. A.R.T. Advisors LLC bought a new stake in ConforMIS during the fourth quarter worth about $178,000. Finally, Creative Planning bought a new stake in ConforMIS during the first quarter worth about $236,000. 39.63% of the stock is currently owned by hedge funds and other institutional investors.
ConforMIS (NASDAQ:CFMS) traded up 0.39% during trading on Friday, reaching $5.14. The company’s stock had a trading volume of 142,362 shares. ConforMIS has a 1-year low of $4.35 and a 1-year high of $13.83. The stock’s market capitalization is $225.23 million. The stock has a 50 day moving average price of $5.08 and a 200 day moving average price of $7.74.
ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zacks-brokerages-expect-conformis-inc-cfms-will-announce-quarterly-sales-of-18-4-million/1737738.html
Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.